MedKoo's News

01/23/2012:  PX-478 available for research.

MedKoo announced today that PX-478 is available for research. PX-478 is a highly water soluble molecule, with good i.v., i.p. and p.o. antitumor activity. It is rapidly absorbed following oral and i.p. administration and gives excellent Cmax and AUC via these routes. For pricing please click  PX-478  to see the detail.

01/03/2012: Anticancer drug canadidates in preclinical study added

MedKoo Biosciences added a new collection of products: anticancer small molecule agents in pre-clinical studies. This page will be updated on weekly basis. Please click the link to see the detail

06/01/2011: Talaporfin sodium available with high qualtiy

Chapel Hill, North Carolina, USA. MedKoo Biosciences is pleased to announce the success of developing a scalable process to make talaporfin sodium with high purity. Talaporfin (INN, also known as aspartyl chlorin, mono-L-aspartyl chlorine e6, NPe6, or LS11) is a photosensitizer used in photodynamic therapy (PDT). It absorbs red light at 664nm normally provided by a laser tuned to this wavelength. It was approved in Japan (in 2004) for PDT of lung cancer and marketed as Laserphyrin.  Please click the link for talaporfin sodium for detail.

02/04/2011: Cabazitaxel available with high quality

Chapel Hill, North Carolina, USA. MedKoo is pleased to announce that  MedKoo and its partner have successfully developed a novel and very efficient synthetic route to make cabazitaxel.  Based on the new synthetic process,  we would be capable to scale up the synthesis. Cabazitaxel was approved in 2010 by FDA and developed by sanofi-aventis.  For chemical structure and product information, please click the link for cabazitaxel for detail. 

Contact MedKoo:

Email: sales@medkoo.com

(Keyword; CAS#; MedKoo code#)